High steap1 expression is associated with improved outcome of ewing's sarcoma patients

Annals of Oncology

Volumn 23, Issue 8, 2012, Pages 2185-2190

  Grunewald, T G P ^a,b   Ranft, A ^c   Esposito, I ^a,d   Da Silva Buttkus, P ^d   Aichler, M ^d   Baumhoer, D ^e   Schaefer, K L ^f   Ottaviano, L ^f   Poremba, C ^f,g   Jundt, G ^e   Jurgens H ^c   Dirksen, U ^c   Richter, G H S ^a   Burdach, S ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^d INSTITUTE OF EPIDEMIOLOGY   (Germany)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

^f HEINRICH HEINE UNIVERSITY   (Germany)

^g Center of Histopathology   (Germany)

Author keywords

Biomarker; Ewing's sarcoma; Outcome; Risk stratification; STEAP1

Indexed keywords

DOXORUBICIN; ETOPOSIDE; MEMBRANE PROTEIN; SIX TRANSMEMBRANE EPITHELIAL ANTIGEN OF THE PROSTATE 1; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; CANCER PROGNOSIS; CELL MEMBRANE; CHILD; DRUG RESPONSE; EWING SARCOMA; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INFANT; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RISK FACTOR; SCHOOL CHILD;

EID: 84864921742     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr605     Document Type: Article

References (48)

1. Burdach S, Thiel U, Schöniger M et al. Total body MRI-governed involved compartment irradiation combined with high-dose chemotherapy and stem cell rescue improves long-term survival in Ewing tumor patients with multiple primary bone metastases. Bone Marrow Transplant 2010; 45(3): 483-489.
2. Burdach S. Treatment of advanced Ewing tumors by combined radiochemotherapy and engineered cellular transplants. Pediatr Transplant 2004; 8 (Suppl 5): 67-82.
3. Burdach S, Jurgens H. High-dose chemoradiotherapy (HDC) in the Ewing family of tumors (EFT). Crit Rev Oncol Hematol 2002; 41(2): 169-189.
4. Thiel U, Wawer A, Wolf P et al. No improvement of survival with reduced- versus high-intensity conditioning for allogeneic stem cell transplants in Ewing tumor patients. Ann Oncol 2011; 22(7): 1614-1621.
5. Burdach S, Jurgens H, Peters C et al. Myeloablative radiochemotherapy and hematopoietic stem-cell rescue in poor-prognosis Ewing's sarcoma. J Clin Oncol 1993; 11(8): 1482-1488.
6. Burdach S, Meyer-Bahlburg A, Laws HJ et al. High-dose therapy for patients with primary multifocal and early relapsed Ewing's tumors: results of two consecutive regimens assessing the role of total-body irradiation. J Clin Oncol 2003; 21(16): 3072-3078.
7. Haeusler J, Ranft A, Boelling T et al. The value of local treatment in patients with primary, disseminated, multifocal Ewing sarcoma (PDMES). Cancer 2010; 116(2): 443-450.
8. Delattre O, Zucman J, Melot T et al. The Ewing family of tumors-a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N Engl J Med 1994; 331(5): 294-299.
9. Staege MS, Hutter C, Neumann I et al. DNA microarrays reveal relationship of Ewing family tumors to both endothelial and fetal neural crest-derived cells and define novel targets. Cancer Res 2004; 64(22): 8213-8221.
10. Le Deley M-C, Delattre O, Schaefer K-L et al. Impact of EWS-ETS fusion type on disease progression in Ewing's sarcoma/peripheral primitive neuroectodermal tumor: prospective results from the cooperative Euro-E.W.I.N.G. 99 trial. J Clin Oncol 2010; 28(12): 1982-1988.
11. Ginsberg JP, de Alava E, Ladanyi M et al. EWS-FLI1 and EWS-ERG gene fusions are associated with similar clinical phenotypes in Ewing's sarcoma. J Clin Oncol 1999; 17(6): 1809-1814.
12. Riley RD, Burchill SA, Abrams KR et al. A systematic review and evaluation of the use of tumour markers in paediatric oncology: Ewing's sarcoma and neuroblastoma. Health Technol Assess 2003; 7(5): 1-162.
13. Cotterill SJ, Ahrens S, Paulussen M et al. Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol 2000; 18(17): 3108-3114.
14. Bui MM, Han G, Acs G et al. Connexin 43 is a potential prognostic biomarker for Ewing sarcoma/primitive neuroectodermal tumor. Sarcoma 2011; 2011: 971050.
15. de Alava E, Antonescu CR, Panizo A et al. Prognostic impact of P53 status in Ewing sarcoma. Cancer 2000; 89(4): 783-792.
16. Lee CK, Lord SJ, Coates AS, Simes RJ. Molecular biomarkers to individualise treatment: assessing the evidence. Med J Aust 2009; 190(11): 631-636.
17. Nishio K, Arao T, Shimoyama T et al. Translational studies for target-based drugs. Cancer Chemother Pharmacol 2005; 56(Suppl 1): 90-93.
18. Grunewald TG, Herbst SM, Heinze J, Burdach S. Understanding tumor heterogeneity as functional compartments-superorganisms revisited. J Transl Med 2011; 9(1): 79.
19. Juergens H, Daw NC, Geoerger B et al. Preliminary efficacy of the anti-insulinlike growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcoma. J Clin Oncol 2011 Dec 1; 29(34): 4534-40. Epub 2011 Oct 24.
20. Thiel U, Pirson S, Müller-Spahn C et al. Specific recognition and inhibition of Ewing tumour growth by antigen-specific allo-restricted cytotoxic T cells. Br J Cancer 2011; 104(6): 948-956.
21. Challita-Eid PM, Morrison K, Etessami S et al. Monoclonal antibodies to sixtransmembrane epithelial antigen of the prostate-1 inhibit intercellular communication in vitro and growth of human tumor xenografts in vivo. Cancer Res 2007; 67(12): 5798-5805.
22. Ohgami RS, Campagna DR, McDonald A, Fleming MD. The Steap proteins are metalloreductases. Blood 2006; 108(4): 1388-1394.
23. Hubert RS, Vivanco I, Chen E et al. STEAP: a prostate-specific cell-surface antigen highly expressed in human prostate tumors. Proc Natl Acad Sci U S A 1999; 96(25): 14523-14528.
24. Grunewald TG, Diebold I, Esposito I et al. STEAP1 is associated with the invasive and oxidative stress phenotype of Ewing tumors. Mol Cancer Res 2012; 10(1): 52-65.
25. Maia CJ, Socorro S, Schmitt F, Santos CR. STEAP1 is over-expressed in breast cancer and down-regulated by 17beta-estradiol in MCF-7 cells and in the rat mammary gland. Endocrine 2008; 34(1-3): 108-116.
26. Valenti MT, Dalle Carbonare L, Donatelli L et al. STEAP mRNA detection in serum of patients with solid tumours. Cancer Lett 2009; 273(1): 122-126.
27. Cheung IY, Feng Y, Danis K et al. Novel markers of subclinical disease for Ewing family tumors from gene expression profiling. Clin Cancer Res 2007; 13(23): 6978-6983.
28. Vaghjiani RJ, Talma S, Murphy CL. Six-transmembrane epithelial antigen of the prostate (STEAP1 and STEAP2)-differentially expressed by murine and human mesenchymal stem cells. Tissue Eng Part A 2009; 15(8): 2073-2083.
29. Tirode F, Laud-Duval K, Prieur A et al. Mesenchymal stem cell features of Ewing tumors. Cancer Cell 2007; 11(5): 421-429.
30. Klein A, Guhl E, Zollinger R et al. Gene expression profiling: cell cycle deregulation and aneuploidy do not cause breast cancer formation in WAP-SVT/t transgenic animals. J Mol Med (Berl) 2005; 83(5): 362-376.
31. Kobayashi H, Nagato T, Sato K et al. Recognition of prostate and melanoma tumor cells by six-transmembrane epithelial antigen of prostate-specific helper T lymphocytes in a human leukocyte antigen class II-restricted manner. Cancer Res 2007; 67(11): 5498-5504.
32. Grunewald TGP, Kammerer U, Kapp M et al. Nuclear localization and cytosolic overexpression of LASP-1 correlates with tumor size and nodal-positivity of human breast carcinoma. BMC Cancer 2007; 7: 198.
33. Grunewald TGP, Kammerer U, Winkler C et al. Overexpression of LASP-1 mediates migration and proliferation of human ovarian cancer cells and influences zyxin localisation. Br J Cancer 2007; 96(2): 296-305.
34. Hayashi S, Kumai T, Matsuda Y et al. Six-transmembrane epithelial antigen of the prostate and enhancer of zeste homolog 2 as immunotherapeutic targets for lung cancer. J Transl Med 2011; 9: 191.
35. Frietsch JJ, Grunewald TGP, Jasper S et al. Nuclear localisation of LASP-1 correlates with poor long-term survival in female breast cancer. Br J Cancer 2010; 102(11): 1645-1653.
36. Salzer-Kuntschik M, Brand G, Delling G. [Determination of the degree of morphological regression following chemotherapy in malignant bone tumors]. Pathologe 1983; 4(3): 135-141.
37. Rodríguez-Galindo C, Liu T, Krasin MJ et al. Analysis of prognostic factors in Ewing sarcoma family of tumors: review of St. Jude Children's Research Hospital studies. Cancer 2007; 110(2): 375-384.
38. López-Guerrero JA, Machado I, Scotlandi K et al. Clinicopathological significance of cell cycle regulation markers in a large series of genetically confirmed Ewing's sarcoma family of tumors. Int J Cancer 2011; 128(5): 1139-1150.
39. Mackintosh C, Ordóñez JL, García-Domínguez DJ et al. 1q gain and CDT2 overexpression underlie an aggressive and highly proliferative form of Ewing sarcoma. Oncogene 2011 Aug 8 [Epub ahead of print].
40. Juergens C, Weston C, Lewis I et al. Safety assessment of intensive induction with vincristine, ifosfamide, doxorubicin, and etoposide (VIDE) in the treatment of Ewing tumors in the EURO-E.W.I.N.G. 99 clinical trial. Pediatr Blood Cancer 2006; 47(1): 22-29.
41. Sanchez-Pulido L, Rojas AM, Valencia A et al. ACRATA: a novel electron transfer domain associated to apoptosis and cancer. BMC Cancer 2004; 4: 98.
42. von Rozycki T, Yen MR, Lende EE, Saier MH. The YedZ family: possible heme binding proteins that can be fused to transporters and electron carriers. J Mol Microbiol Biotechnol 2004; 8(3): 129-140.
43. Kamata T. Roles of Nox1 and other Nox isoforms in cancer development. Cancer Sci 2009; 100(8): 1382-1388.
44. Lambeth JD. NOX enzymes and the biology of reactive oxygen. Nat Rev Immunol 2004; 4(3): 181-189.
45. Pan YZ, Li Y, Guo LR et al. [Influence of expression of six transmembrane epithelial antigen of the prostate-1 on intracellular reactive oxygen species level and cell growth: an in vitro experiment]. Zhonghua Yi Xue Za Zhi 2008; 88(9): 641-644.
46. Mailloux RJ, Adjeitey CN, Harper ME. Genipin-induced inhibition of uncoupling protein-2 sensitizes drug-resistant cancer cells to cytotoxic agents. PLoS One 2010; 5(10): e13289.
47. Sun Y, St Clair DK, Xu Y et al. A NADPH oxidase-dependent redox signaling pathway mediates the selective radiosensitization effect of parthenolide in prostate cancer cells. Cancer Res 2010; 70(7): 2880-2890.
48. Girdhani S, Bhosle SM, Thulsidas SA et al. Potential of radiosensitizing agents in cancer chemo-radiotherapy. J Cancer Res Ther 2005; 1(3): 129-131.